Dengue monoclonal antibody - Serum Institute of India
Alternative Names: DengushieldLatest Information Update: 28 Apr 2022
Price :
$50 *
At a glance
- Originator Serum Institute of India
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dengue
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Dengue(In volunteers) in Australia (IV, Injection)
- 23 Dec 2019 Serum Institute of India completes a phase I trial in Dengue (In volunteers) in Australia (IV) (NCT03883620)
- 20 Mar 2019 Phase-I clinical trials in Dengue (In volunteers) in Australia (IV) (NCT03883620)